Anxiety, Depression, Parkinson Disease
Conditions
Keywords
Parkinson Disease, Anxiety, Depression
Brief summary
Behavioral Treatments for Anxiety and Depression (BehTA-D) is a research study for anxiety and depression in individuals with Parkinson's disease (PD). The research clinicians try to teach skills that may help participants cope with anxiety and depression in the context of Parkinson's disease. Research clinicians will also discuss ways improve management of Parkinson's symptoms. Other skills taught include how to relax, change thinking, add in meaningful pleasant activity.
Detailed description
Components of evidence-based cognitive behavioral therapy (CBT) treatments from current manuals developed for depression and anxiety will be used to construct the 8-week treatment program. The flexibility of modular based treatment allows patients and counselors to personalize interventions and skills for managing anxiety and depressive symptoms. The first treatment session will be in-person. All following sessions will be provided by telephone. Caregivers will have the option of being involved in 2 ways throughout treatment - as a coach to facilitate use of new skills by their loved one with PD and as a recipient of stress- management support. The scope of caregiver involvement will vary across patients, based on their preference. Involved caregivers will be given the opportunity to participate in 1 telephone-based stress-management session and 1 follow-up call scheduled individually during the first 4 weeks of treatment.
Interventions
BEHAVIORALCognitive Behavioral Therapy
A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
Sponsors
South Central VA Mental Illness Research, Education & Clinical Center
Michael E. DeBakey VA Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Have a confirmed diagnosis of idiopathic Parkinson's disease 2. Have significant anxiety and/or depressive symptoms as indicated by a score of greater than 4 on the Geriatric Depression Scale -15 or greater than 5 on the Hospital Anxiety and Depression anxiety subscale
Exclusion criteria
Patients will be excluded if they have cognitive impairment as indicated by the Montreal Cognitive Assessment (MoCA \< 23) or if they have a condition that threatens their safety or life including suicidal intent, current psychosis, bipolar, substance abuse or impulse control disorders within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospital Anxiety and Depression Scale and Hamilton Anxiety Scale | Baseline, 3-months and 4-months |
| Hamilton Depression Scale and Geriatric Depression Scale - 15 | Baseline, 3-months, and 4-months |
Secondary
| Measure | Time frame |
|---|---|
| Parkinson's Disease Questionnaire -8 | Baseline, 3-months and 4-months |
| Client Satisfaction Questionnaire | 3-months and 4-months |
Countries
United States
Outcome results
None listed